Epigenetic Drug Targets Fat, Improving Blood Vessel Health

Why It Matters

By targeting the fat‑vessel interface rather than downstream risk factors, epigenetic therapy could prevent endothelial dysfunction, a primary trigger of heart attacks and heart failure, offering a novel preventive strategy for cardiometabolic disease.

Key Takeaways

• BET inhibitor RVX-208 restores vessel relaxation in obese hypertensive patients
• Perivascular adipose tissue drives inflammation; targeting it improves endothelial function
• HK2 downregulation mediates anti‑inflammatory effects of epigenetic therapy
• Benefits double with intact PVAT, highlighting fat‑vessel signaling
• Early‑stage epigenetic therapy may outperform late‑stage cardiovascular trials

Pulse Analysis

Cardiometabolic disease (CMD) remains a leading cause of cardiovascular mortality in the United States, driven by the twin epidemics of obesity and hypertension. A critical early event in CMD is endothelial dysfunction, where the inner lining of blood vessels loses its ability to produce nitric oxide and dilate on demand. Recent research has shifted attention from the endothelial cells themselves to the surrounding perivascular adipose tissue (PVAT), a thin fat layer that exchanges biochemical signals with the vessel wall. In healthy individuals, PVAT releases vasodilatory factors, but in obesity it becomes pro‑inflammatory, tightening vessels and accelerating disease progression.

In a paper published in Cell Reports, researchers from the University of Zurich applied RVX‑208, a small‑molecule BET (bromodomain and extra‑terminal) inhibitor, to human arterial segments harvested from 27 obese, hypertensive patients. BET proteins read acetyl‑marked histones and amplify stress‑responsive gene programs; blocking them lowered reactive oxygen species, restored nitric oxide, and silenced cytokines such as IL‑1β, IL‑6, and TNF‑α. The therapeutic effect was strongest when PVAT remained attached, indicating that the fat depot drives the pathological signal. Parallel mouse experiments pinpointed hexokinase‑2 (HK2) as a downstream metabolic node; both genetic knock‑down and a selective HK2 inhibitor reproduced the vascular benefits, linking glycolytic flux to inflammation.

The study opens a new therapeutic avenue that targets the epigenetic regulation of PVAT rather than conventional downstream risk factors like blood pressure or cholesterol. Early‑stage epigenetic modulation could halt the cascade that leads to arterial stiffening, offering a preventive strategy for patients before irreversible vascular damage occurs. While BET inhibitors have already entered cardiovascular trials, those enrolled late‑stage patients with extensive damage, possibly dampening observable outcomes. Future clinical programs that enroll individuals with early CMD and combine BET inhibition with HK2 targeting may deliver more robust improvements in endothelial health and reduce long‑term cardiovascular events.